The US general anesthesia drugs market is projected to reach USD 2.4 billion by 2025 from USD 2 billion in 2020, at a CAGR of 3.4% during the forecast period.
The major factors driving the growth of this market are the rapid growth in geriatric population, rising prevalence of cancer and increasing number of emergency surgeries. However, issues related to the side effects of general anesthesia drugs in pregnant women and children are likely to restrain the market growth to a certain extent.
By route of administration, the intravenous drugs accounted for the largest share of the US general anesthesia drugs market
The intravenous drugs segment is expected to account for the largest market share in 2020. Factors such rapid onset of action, introduction of new anesthesia drugs with desired pharmacologic effects is expected to drive the market of intravenous anesthesia drugs. Moreover, intravenous anesthesia drugs are less expensive and do not require expensive machines for administration which contributes to the high market share of the segment.
Among intravenous anesthesia drugs, propofol accounted for the major share of the market in 2020. Smooth onset of action, high rate of total body clearance and less side effects are some of the factors contributing to high uptake of propofol as an anesthetic agent.
By End-user, Hospitals accounted for the largest share of the US general anesthesia drugs market
The hospitals segment accounted for the largest share of the US general anesthesia drugs market in 2019. The massive patient footfall in hospitals and the increasing number of surgeries performed in these facilities are the factors responsible for the largest share of the segment.
Research Coverage
The report segments the US general anesthesia drugs market based on route of administration ((inhalational (sevoflurane, desflurane, isoflurane and nitrous oxide) and intravenous (propofol, benzodiazepines, ketamine, methohexital sodium and others)) and end-user (hospitals and ambulatory surgery centers). Company type (Tier 1, tier 2, Tier 3 providers of general anesthesia drugs). The report also provides a comprehensive review of market drivers, challenges, and opportunities in the US general anesthesia drugs market.
The US general anesthesia drugs market is dominated by a few established players such as Baxter International Inc. (US), Hikma Pharmaceuticals plc (UK), Pfizer Inc. (US), Piramal Enterprises Limited (India), AbbVie (US), Fresenius SE & Co. KGaA (Germany), Par Pharmaceutical (US), Teva Pharmaceuticals (Israel), Viatris/Mylan (US), Novartis AG (US), Abbott Laboratories (US), AstraZeneca plc (US), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (UK), Gilead Sciences, Inc. (US), Bayer AG (Germany), Merck & Co., Inc. (Germany), Sanofi (France), Heritage Pharmaceuticals Inc. (US), Akorn (US), and Apotex (Canada).
Breakdown of Primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:
- By Respondent: Supply Side - 80%, Demand Side - 20%
- By Designation: Executives - 25%, CXOs - 20%, Managers - 55%
Key Benefits of Buying the Report
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the US general anesthesia drugs market and provides them information on key market drivers, challenges, and opportunities.
Table of Contents
1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
1.7 Summary of Changes
2 Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.2 Primary Data
Figure 1 Breakdown of Primaries: US General Anesthesia Drugs Market
2.1.3 Market Data Estimation & Triangulation
Figure 2 Data Triangulation Methodology
2.2 Market Estimation Methodology
Figure 3 Market Size Estimation (Company Revenue Analysis-Based Estimation)
Figure 4 US General Anesthesia Drugs Market Size (USD Million)
Figure 5 US General Anesthesia Drugs Market: Growth Rate of Top Companies (2018-2019)
Figure 6 US General Anesthesia Drugs Market: Final CAGR Projections (2020-2025)
2.3 Industry Insights
2.4 Assumptions for the Study
3 Executive Summary
Figure 7 US General Anesthesia Drugs Market, by Route of Administration, 2020 vs. 2025 (USD Million)
Figure 8 US General Anesthesia Drugs Market for Intravenous General Anesthetics, by Type, 2020 vs. 2025 (USD Million)
Figure 9 US General Anesthesia Drugs Market for Inhalational General Anesthetics, by Type, 2020 vs. 2025 (USD Million)
4 Premium Insights
4.1 US General Anesthesia Drugs Market Overview
Figure 10 Increasing Number of Emergency Surgeries and the Rapidly Growing Aging Population to Drive Market Growth
4.2 US General Anesthesia Drugs Market, by End-user, 2020 Vs. 2025
Figure 11 Hospitals Hold the Largest Share of the US General Anesthesia Drugs Market
5 Market Overview
5.1 Market Analysis
5.2 Market Dynamics
Figure 12 US General Anesthesia Drugs Market: Drivers, Restraints, and Opportunities
5.2.1 Drivers
5.2.1.1 Rapid Growth in the Geriatric Population
5.2.1.2 Rising Prevalence of Cancer
5.2.1.3 Rising Number of Emergency Surgeries
5.2.2 Restraints
5.2.2.1 Risks Associated with General Anesthesia in Pediatric Patients and Pregnant Women
Table 1 List of General Anesthetics and Sedation Drugs Affected by Label Change
5.2.3 Opportunities
5.2.3.1 Patent Expiry of Lusedra
5.3 Market Size
5.3.1 Historical Market Trends, 2016-2019
Figure 13 US Ketamine Market, 2016-2019 (USD Million)
5.3.2 Market Forecasts, 2020-2025
Figure 14 US Ketamine Market, 2020-2025 (USD Million)
5.4 Impact of COVID-19 on the Growth of the US General Anesthesia Drugs Market
6 Distribution Structure
6.1 US Ketamine Market: Distribution Structure
Figure 15 Distribution Structure
Table 2 US: Ketamine Market, by Distribution Channel, 2016-2019 (USD Million)
Table 3 US: Ketamine Market, by Distribution Channel, 2020-2025 (USD Million)
6.1.1 US Ketamine Market, by Manufacturer
Table 4 US: Ketamine Market, by Manufacturer, 2016-2019 (USD Million)
Table 5 US: Ketamine Market, by Manufacturer, 2016-2019 (Kilogram)
Table 6 US: Ketamine Market, by Manufacturer, 2020-2025 (USD Million)
Table 7 US: Ketamine Market, by Manufacturer, 2020-2025 (Kilogram)
6.1.2 US Ketamine Market, by Distribution Channel
6.1.2.1 Group Purchasing Organizations
Figure 16 US Ketamine Market Share, by GPO (2019)
Table 8 US: Ketamine Market, by GPO, 2016-2019 (USD Million)
Table 9 US: Ketamine Market, by GPO, 2016-2019 (Kilogram)
Table 10 US: Ketamine Market, by GPO, 2020-2025 (USD Million)
Table 11 US: Ketamine Market, by GPO, 2020-2025 (Kilogram)
6.1.2.2 Distributors
Figure 17 US Ketamine Market Share, by Distributor (2019)
Table 12 US: Ketamine Market, by Distributor, 2016-2019 (USD Million)
Table 13 US: Ketamine Market, by Distributor, 2016-2019 (Kilogram)
Table 14 US: Ketamine Market, by Distributor, 2020-2025 (USD Million)
Table 15 US: Ketamine Market, by Distributor, 2020-2025 (Kilogram)
6.2 Key Legal Trends for Controlled Substances
6.2.1 Compliance Associated with the Manufacturing of Narcotics in the US
6.2.1.1 Registration
6.2.1.2 Security
6.2.1.3 Labeling and Packaging
6.2.1.4 Inventory
6.2.1.5 Records
6.2.2 Compliance Associated with Vendors of Narcotics in the US
6.3 Product Category Enumeration
6.3.1 Ketamine
6.3.2 Other Brands
7 US General Anesthesia Drugs Market: Key Information
7.1 Import & Export Systems in the US
7.1.1 Import of Controlled Substances
7.1.1.1 Shipment of Controlled Substances
7.1.1.2 Registration of Applicants for the Import and Export of Controlled Substances
7.1.2 Export of Controlled Substances
7.1.2.1 Exceptions in Exportation for Special Scientific Purposes
7.1.2.2 Custom Tariffs for Imports
Table 16 Harmonized Tariff Schedule for Anesthesia Drugs
Table 17 Anesthesia Molecules: Chemical Abstracts Services Numbers
7.1.3 Transport of Controlled Substances
7.1.4 Customs Clearance
Figure 18 Customs Clearance Procedure for Imported Controlled Substances in the US
Figure 19 Export Customs Clearance Procedure for Controlled Substances in the US
7.1.5 Non-Tariff Barriers
Table 18 Regulatory Requirements for Controlled Substances
7.2 Top Related Exhibitions
Table 19 Anesthesia Exhibitions/Workshops/Conferences in the US
7.3 Description of Potential Buyers
Table 20 Potential Group Purchasing Organizations
Table 21 Potential Distributors
Figure 20 Business Strategy
8 Product Analysis
8.1 Anesthesia Drugs Market Segmentation in the US
Figure 21 Anesthesia Drugs Market Segmentation
Figure 22 Location Quotient of Anesthesia Specialists in the US, by State (May 2019)
Figure 23 Anesthesia Landscape
Table 22 Anesthesia Drugs Market, by Type, 2016-2019 (USD Million)
Table 23 Anesthesia Drugs Market, by Type, 2020-2025 (USD Million)
8.2 General Anesthesia
8.2.1 Introduction
8.2.2 General Anesthesia Drugs Market Segmentation
Figure 24 Segmentation of the General Anesthesia Drugs Market
Table 24 US: General Anesthesia Drugs Market, by Route of Administration, 2016-2019 (USD Million)
Table 25 US: General Anesthesia Drugs Market, by Route of Administration, 2020-2025 (USD Million)
8.3 Intravenous General Anesthetics
Table 26 US: Intravenous General Anesthetics Market, by Type, 2016-2019 (USD Million)
Table 27 US: Intravenous General Anesthetics Market, by Type, 2020-2025 (USD Million)
8.4 Inhalational General Anesthetics
Table 28 US: Inhalational General Anesthetics Market, by Type, 2016-2019 (USD Million)
Table 29 US: Inhalational General Anesthetics Market, by Type, 2020-2025 (USD Million)
8.4.1 Major Brands/Molecules
8.4.1.1 Propofol
8.4.1.2 Benzodiazepines
8.4.1.3 Methohexital Sodium
8.5 Competition in the US
Figure 25 Properties of Intravenous Anesthesia Drugs
Figure 26 Intravenous General Anesthetics Market, by Molecule, 2019 (USD Million)
8.5.1 Sales Price
Table 30 Propofol Price, 2020 (USD)
Table 31 Midazolam Price, 2020 (USD)
Table 32 Methohexital Sodium Price, 2020 (USD)
Table 33 Etomidate Price, 2020 (USD)
Table 34 Ketamine Price, 2020 (USD)
8.5.2 Major Brands
Table 35 General Intravenous Anesthesia Drugs: Usage Trends
8.6 Potential Buyers in the US
8.6.1 Potential Buyers, by State
Table 36 Group Purchasing Organizations, by State
Table 37 Distributors, by State
9 US General Anesthesia Drugs Market, by End-user
9.1 Introduction
Table 38 US: General Anesthesia Drugs Market, by End-user, 2016-2019 (USD Million)
Table 39 US: General Anesthesia Drugs Market, by End-user, 2020-2025 (USD Million)
9.1.1 Hospitals
9.1.1.1 Growing Patient Pool in Hospitals to Drive Market Growth
9.1.2 Ambulatory Surgery Centers
9.1.2.1 Increasing Number of ASCs in the Country to Boost the Market Growth
10 Competitive Landscape
10.1 Overview
10.2 Market Share Analysis (2019)
Figure 27 US General Anesthesia Drugs Market Share, by Key Player, 2019
10.3 Key Market Developments
10.3.1 Product Launches
10.3.2 Acquisitions
10.3.3 Expansions
10.3.4 Partnerships
11 Company Evaluation Matrix and Company Profiles
11.1 Overview
11.2 Competitive Leadership Mapping: Major Market Players (2019)
11.2.1 Stars
11.2.2 Emerging Leaders
11.2.3 Pervasive Players
11.2.4 Participants
Figure 28 US General Anesthesia Drugs Market: Competitive Leadership Mapping, 2019
12 Company Profiles
(Business Overview, Products Offered, Recent Developments, Analyst's View)*
12.1 Pfizer, Inc.
Figure 29 Pfizer, Inc.: Company Snapshot (2019)
12.2 Fresenius SE & Co. KGaA
Figure 30 Fresenius SE & Co. KGaA: Company Snapshot (2019)
12.3 Baxter International Inc.
Figure 31 Baxter International Inc.: Company Snapshot (2019)
12.4 Hikma Pharmaceuticals plc
Figure 32 Hikma Pharmaceuticals plc: Company Snapshot (2019)
12.5 Abbvie
Figure 33 Abbvie: Company Snapshot (2019)
12.6 Piramal Enterprises Limited
Figure 34 Piramal Enterprises Limited: Company Snapshot (2020)
12.7 Abbott Laboratories
Figure 35 Abbott Laboratories: Company Snapshot (2019)
12.8 Astrazeneca plc
Figure 36 Astrazeneca plc: Company Snapshot (2019)
12.9 Novartis AG
Figure 37 Novartis AG: Company Snapshot (2019)
12.10 F. Hoffmann-La Roche Ltd.
Figure 38 F. Hoffmann-La Roche Ltd.: Company Snapshot (2019)
12.11 Bayer AG
Figure 39 Bayer AG: Company Snapshot (2019)
12.12 GlaxoSmithKline plc
Figure 40 GlaxoSmithKline plc: Company Snapshot (2019)
12.13 Gilead Sciences
Figure 41 Gilead Sciences: Company Snapshot (2019)
12.14 Merck & Co. Inc.
Figure 42 Merck & Co. Inc.: Company Snapshot (2019)
12.15 Sanofi
Figure 43 Sanofi: Company Snapshot (2019)
12.16 PAR Pharmaceutical
12.17 Teva Pharmaceuticals
12.18 Viatris (Mylan)
12.19 Heritage Pharmaceuticals Inc.
12.20 Akorn
12.21 Apotex
*Business Overview, Products Offered, Recent Developments, Analyst's View Might Not be Captured in Case of Unlisted Companies
13 Appendix
13.1 Discussion Guide
13.2 Knowledge Store
Companies Mentioned
- Abbott Laboratories
- Abbvie
- Akorn
- Apotex
- Astrazeneca plc
- Baxter International Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Fresenius SE & Co. KGaA
- Gilead Sciences
- GlaxoSmithKline plc
- Heritage Pharmaceuticals Inc.
- Hikma Pharmaceuticals plc
- Merck & Co. Inc.
- Novartis AG
- PAR Pharmaceutical
- Pfizer, Inc.
- Piramal Enterprises Limited
- Sanofi
- Teva Pharmaceuticals
- Viatris (Mylan)
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 117 |
| Published | February 2021 |
| Forecast Period | 2020 - 2025 |
| Estimated Market Value ( USD | $ 2 billion |
| Forecasted Market Value ( USD | $ 2.4 billion |
| Compound Annual Growth Rate | 3.7% |
| Regions Covered | United States |
| No. of Companies Mentioned | 21 |
